In addition, pancancer progression-free interval (PFI) analysis in TCGA revealed that ALYREF is an unfavorable factor in kidney chromophobe, uveal melanoma, glioma, and hepatocellular carcinoma (Additional file 2: Fig. S12E). Here, ALYREF is linked to glioma.